Vaxcyte Announces FDA Clearance for VAX-31 Infant Phase 2 Study and Breakthrough Therapy Designation for Adult Phase 3 Study
Vaxcyte Announces FDA Clearance for VAX-31 Infant Phase 2 Study and Breakthrough Therapy Designation for Adult Phase 3 Study
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.